POPULARITY
14 episodes with hnscc
16 episodes with hnscc
12 episodes with hnscc
4 episodes with hnscc
6 episodes with hnscc
3 episodes with hnscc
3 episodes with hnscc
4 episodes with hnscc
2 episodes with hnscc
Check out this week's QuadCast with many highlights from ASCO, including adding nivo to postop CRT in HNSCC, the benefits of immunotherapy in resected MMRd colon cancer, how SRS beat HA-WBRT, and more. Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom
Check out this week's QuadCast as we highlight SRS vs. fSRS for hearing preservation in vestibular schwannomas, preoperative immunotherapy in HNSCC, and much more. Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom
W tym odcinku zagłębiamy się w świat kanabichromenu (CBC) – jednego z mniej znanych, ale niezwykle obiecujących fitokanabinoidów. Naszym gościem jest Izabela Piątek, współwłaścicielka Polskiej Grupy Kapitałowej 3H, ekspertka od badań i rozwoju w branży konopnej. Dowiesz się, dlaczego CBC nazywany jest „czarnym koniem” w leczeniu depresji, jak działa na układ nerwowy, skórę oraz stany zapalne.Porozmawiamy także o jego potencjale w terapii bólu migrenowego, nowotworów i problemów jelitowych. Ale to nie wszystko – Izabela Piątek zdradza kulisy produkcji kosmetyków konopnych, radzi, jak rozpoznać wysokiej jakości ekstrakty i unikać oszustów na rynku.Jeśli interesuje Cię, jak nauka odkrywa tajemnice konopi oraz jakie są perspektywy rozwoju tej branży, ten odcinek jest dla Ciebie. Przygotuj się na sporą dawkę wiedzy, ciekawostek i praktycznych wskazówek. Włącz i posłuchaj już teraz!
In today's episode, supported by PDS Biotech, we had the pleasure of speaking with Kevin Harrington, MD, PhD, FRCP, FRCR, FRSB, about the role of PDS0101 (Versamune HPV) in patients with human papillomavirus type 16 (HPV16)–positive head and neck squamous cell carcinoma (HNSCC). Dr Harrington is head of the Division of Radiotherapy and Imaging at The Institute of Cancer Research in London, United Kingdom, as well as a fellow of the Royal College of Physicians and the Royal College of Radiologists. In our exclusive interview, Dr Harrington discussed current unmet needs for patients with recurrent/metastatic HNSCC, the rationale for the continued investigation of PDS0101 plus pembrolizumab (Keytruda) in patients with HPV16-positive HNSCC, and how the ongoing phase 3 VERSATILE-003 trial may change the treatment paradigm for patients with this disease.
Dr. Deborah Wong, Director of the Medical Oncology Program and Clinical Trials Program for Head and Neck Squamous Cell Cancers (HNSCC) and an Associate Clinical Professor of Medicine at the University of California Los Angeles (UCLA) is currently serving as co-chair of i3 Health's accredited CME/NCPD activity, Recurrent and Metastatic HNSCC, Harnessing Immunotherapy and Comprehensive Care. With new developments in the field occurring over recent months, Dr. Wong sat down with us again to share new updates in treatment and management of HNSCC. Click here for the full activity: https://i3health.com/course-information/hnscc-harnessing-immunotherapy-in-comprehensive-care
BUFFALO, NY- July 22, 2024 – A new #research paper was #published in Oncotarget's Volume 15 on July 10, 2024, entitled, “Improved efficacy of pembrolizumab combined with soluble EphB4-albumin in HPV-negative EphrinB2 positive head neck squamous cell carcinoma.” Patients with relapsed or metastatic head and neck squamous cell carcinoma (HNSCC) after primary local therapy have low response rates with cetuximab, systemic chemotherapy or check point inhibitor therapy. Novel combination therapies with the potential to improve outcomes for patients with HNSCC is an area of high unmet need. In this new study, researchers Alexandra Jackovich, Barbara J. Gitlitz, Justin Wayne Wong Tiu-lim, Vinay Duddalwar, Kevin George King, Anthony B. El-Khoueiry, Jacob Stephen Thomas, Denice Tsao-Wei, David I. Quinn, Parkash S. Gill, and Jorge J. Nieva from Rutgers New Jersey Medical School and the University of Southern California conducted a phase II single-arm clinical trial of locally advanced or metastatic HNSCC patients treated with a combination of soluble EphB4-human serum albumin (sEphB4-HSA) fusion protein and pembrolizumab after platinum-based chemotherapy with up to 2 prior lines of treatment. “sEphB4-HSA in combination with pembrolizumab has a safety profile similar to what has been observed previously with no overlapping toxicity.” The primary endpoints were safety and tolerability and the primary efficacy endpoint was overall response rate (ORR). Secondary endpoints included progression free survival (PFS) and overall survival (OS). HPV status and EphrinB2 expression were evaluated for outcome. Twenty-five patients were enrolled. Median follow up was 40.4 months (range 9.8 – 40.4). There were 6 responders (ORR 24%). There were 5 responders in the 11 HPV-negative and EphrinB2 positive patients, (ORR 45%) with 2 of these patients achieving a complete response (CR). The median PFS in HPV-negative/EphrinB2 positive patients was 3.2 months (95% CI 1.1, 7.3). Median OS in HPV-negative/EphrinB2 positive patients was 10.9 months (95% CI 2.0, 13.7). Hypertension, transaminitis and fatigue were the most common toxicities. “The combination of sEphB4-HSA and pembrolizumab has a favorable toxicity profile and favorable activity particularly among HPV-negative EphrinB2 positive patients with HNSCC.” DOI - https://doi.org/10.18632/oncotarget.28605 Correspondence to - Alexandra Jackovich - atj41@njms.rutgers.edu, and Jorge J. Nieva - jorge.nieva@med.usc.edu Video short - https://www.youtube.com/watch?v=8SVmHYQigwA Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28605 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, EphrinB2, EphB4, HNSCC, pembrolizumab, HPV-negative About Oncotarget Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science). To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM
Check out this week's Quadcast where we highlight the role of FMISO PET to identify tumor hypoxia for attempts at dose de-escalation in HPV mediated HNSCC, ASTRO's new guidelines on bone metastasis treatment, SBRT for mediastinal LNs, and more. Check out the website and subscribe to the newsletter! www.quadshotnews.com Founders & Lead Authors: Laura Dover & Caleb Dulaney Podcast Host: Sam Marcrom
CME credits: 0.50 Valid until: 03-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/overcoming-barriers-to-equitable-care-in-hnscc/24357/ In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.
CME credits: 0.50 Valid until: 03-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/optimizing-first-line-immunotherapy-for-recurrent-or-metastatic-hnscc/24359/ In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.
CME credits: 0.50 Valid until: 03-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/program-name/24359/ In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.
CME credits: 0.50 Valid until: 03-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/program-name/24357/ In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.
CME credits: 0.50 Valid until: 03-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/the-role-of-immunotherapy-in-the-treatment-of-recurrent-or-metastatic-hnscc-the-evidence/24355/ In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.
Host: Nabil F. Saba, MD, FACP Guest: Barbara Burtness, MD In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.
Host: Nabil F. Saba, MD, FACP Guest: Barbara Burtness, MD In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.
Host: Nabil F. Saba, MD, FACP Guest: Barbara Burtness, MD In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.
Host: Nabil F. Saba, MD, FACP Guest: Barbara Burtness, MD In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.
Host: Nabil F. Saba, MD, FACP Guest: Barbara Burtness, MD In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.
In this video, Dr. Assuntina G. Sacco, Associate Professor of Internal Medicine, Co-Director of the Hanna and Mark Gleiberman Head and Neck Cancer Center, and Disease Team Leader–Head and Neck at UC San Diego Moores Cancer Center, answers questions asked by the audience during her CME/NCPD–approved activity with i3 Health, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: New Insights and Real-World Evidence for Improved Patient Outcomes. Dr. Sacco shares insights into targeted mutations to test for, recommendations for patient education, the future of HPV therapeutic vaccines, monitoring for immune-related adverse events, and more! Claim free CME/NCPD credit for Dr. Sacco's activity here: https://www.i3health.com/course-information/recurrent-and-metastatic-hnscc-new-insights-and-real-world-evidence-for-improved-patient-outcomes
In celebration of Head and Neck Cancer Awareness Month this April, Oncology Data Advisor Fellows Forum and Editorial Board Members Samuel Kareff, MD, MPH; Matthew Hadfield, DO; and Nagashree Seetharamu, MD, sat down to discuss the epidemiology of head and neck squamous cell carcinomas (HNSCC), the diagnostic and treatment process of HNSCC, including: –Epidemiologic trends –Geographic distribution –Approved screening methods –Novel treatment combinations –Side effects and adverse events –Survivorship –And more!
Head and neck squamous cell carcinoma (HNSCC) is a prevalent and heterogeneous form of cancer that affects thousands of individuals worldwide. The prognosis for HNSCC patients can vary greatly, depending on factors such as tumor stage and site. The tumor microenvironment (TME) plays a crucial role in tumorigenesis and disease progression, with cellular senescence being a key component. Senescent cells, characterized by cell-cycle arrest, have been shown to have both tumor-suppressive and tumor-promoting effects. However, the prognostic significance of senescence-related TME genes in HNSCC remains poorly understood. In a new study, researchers Young Chan Lee, Yonghyun Nam, Minjeong Kim, Su Il Kim, Jung-Woo Lee, Young-Gyu Eun, and Dokyoon Kim from Kyung Hee University, Kyung Hee University Hospital at Gangdong, and the University of Pennsylvania aimed to investigate the prognostic significance of senescence-related TME genes in HNSCC and their potential implications for immunotherapy response. They utilized data from The Cancer Genome Atlas (TCGA) to identify two distinct subtypes of HNSCC based on the expression of senescence-related TME genes. The team then constructed a risk model consisting of senescence-related TME core genes (STCGs) and validated its prognostic capability in independent cohorts. Their research paper was chosen as an Aging cover paper and published in Volume 16, Issue 2, entitled, “Prognostic significance of senescence-related tumor microenvironment genes in head and neck squamous cell carcinoma.” Full blog - https://aging-us.org/2024/02/senescence-related-tme-genes-as-key-prognostic-predictors-in-hnscc/ Paper DOI - https://doi.org/10.18632/aging.205346 Corresponding authors - Young-Gyu Eun - ygeun@khu.ac.kr, and Dokyoon Kim - dokyoon.kim@pennmedicine.upenn.edu Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.205346 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, cellular senescence, head and neck cancer, immunotherapy, microenvironment, single cell About Aging-US Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways. Please visit our website at https://www.Aging-US.com and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc Media Contact 18009220957 MEDIA@IMPACTJOURNALS.COM
BUFFALO, NY- January 24, 2024 – A new #research paper was #published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 1, entitled, “Targeting of FSP1 regulates iron homeostasis in drug-tolerant persister head and neck cancer cells via lipid-metabolism-driven ferroptosis.” Research has demonstrated that some tumor cells can transform into drug-tolerant persisters (DTPs), which serve as a reservoir for the recurrence of the disease. In this new study, researchers Yang-Che Wu, Chin-Sheng Huang, Ming-Shou Hsieh, Chih-Ming Huang, Syahru Agung Setiawan, Chi-Tai Yeh, Kuang-Tai Kuo, and Shao-Cheng Liu from Taipei Medical University-Shuang Ho Hospital, Taipei Medical University, Taitung Mackay Memorial Hospital, Tajen University, National Taitung University, and Taipei City's National Defense Medical Center investigated lipid-metabolism-driven ferroptosis and its role in drug resistance and DTP generation in head and neck squamous cell carcinoma (HNSCC). “The regulatory roles of ferroptosis suppressor protein 1 (FSP1) in HNSCC metabolic regulation were investigated.” High levels of FSP1 were discovered in the tissues of patients who experienced relapse after cisplatin treatment. RNA sequencing indicated that a series of genes related to lipid metabolism were also highly expressed in tissues from these patients. Consistent results were obtained in primary DTP cells isolated from patients who experienced relapse. The Cancer Genome Atlas database confirmed this finding. This revealed that the activation of drug resistance in cancer cells is influenced by FSP1, intracellular iron homeostasis, and lipid metabolism. Next, the team generated human oral squamous cell carcinoma DTP cells (HNSCC cell line) to cisplatin and observed higher expression of FSP1 and lipid-metabolism-related targets in vitro. The shFSP1 blockade attenuated HNSCC-DTP cell stemness and downregulated tumor invasion and the metastatic rate. They found that cisplatin induced FSP1/ACSL4 axis expression in HNSC-DTPC cells. Finally, the researchers evaluated the HNSCC CSC-inhibitory functions of iFSP1 (a metabolic drug and ferroptosis inducer) used for neo-adjuvant chemotherapy; this was achieved by inducing ferroptosis in a patient-derived xenograft mouse model. “The present findings elucidate the link between iron homeostasis, ferroptosis, and cancer metabolism in HNSCC-DTP generation and acquisition of chemoresistance. The findings may serve as a suitable model for cancer treatment testing and prediction of precision treatment outcomes. In conclusion, this study provides clinically oriented platforms for evaluating metabolism-modulating drugs (FSP1 inhibitors) and new drug candidates of drug resistance and ferroptotic biomarkers.” Corresponding authors - Ming-Shou Hsieh - 22057@s.tmu.edu.tw, and Shao-Cheng Liu - m871435@mail.ndmctsgh.edu.tw About Aging-US Launched in 2009, Aging-US publishes papers of general interest and biological significance in all fields of aging research and age-related diseases, including cancer—and now, with a special focus on COVID-19 vulnerability as an age-dependent syndrome. Topics in Aging-US go beyond traditional gerontology, including, but not limited to, cellular and molecular biology, human age-related diseases, pathology in model organisms, signal transduction pathways (e.g., p53, sirtuins, and PI-3K/AKT/mTOR, among others), and approaches to modulating these signaling pathways. Please visit our website at https://www.Aging-US.com and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM
Please visit answersincme.com/EXA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma. Upon completion of this activity, participants should be better able to: Outline guideline-recommended approaches to the first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) using PD-1 inhibitors; Review the latest clinical data for first-line PD-1 inhibitor–based therapies in the treatment of patients with R/M HNSCC; and Describe clinical strategies to optimize management of patients with R/M HNSCC treated with PD-1 inhibitors.
Please visit answersincme.com/EXA860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma. Upon completion of this activity, participants should be better able to: Outline guideline-recommended approaches to the first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) using PD-1 inhibitors; Review the latest clinical data for first-line PD-1 inhibitor–based therapies in the treatment of patients with R/M HNSCC; and Describe clinical strategies to optimize management of patients with R/M HNSCC treated with PD-1 inhibitors.
Please visit answersincme.com/EEF860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in head and neck squamous cell carcinoma (HNSCC) discusses the clinical significance of emerging antagonists of inhibitors of apoptosis proteins (IAPs) for patients with HNSCC. Upon completion of this activity, participants should be better able to: Describe the biologic rationale for emerging antagonists of IAPs for patients with resectable and unresectable locally advanced (LA) HNSCC; Review the clinical significance of emerging antagonists of IAPs in the treatment of unresectable LA HNSCC, based on the latest efficacy and safety data; and Outline strategies for how antagonists of IAPs may fit into future treatment algorithms for patients with resectable and unresectable LA HNSCC, as they become available.
A new research perspective was published in Oncotarget's Volume 14 on May 10, 2023, entitled, “HER3- A key survival pathway and an emerging therapeutic target in metastatic colorectal cancer and pancreatic ductal adenocarcinoma.” Colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC) are highly metastatic cancers with poor survival rates. The tumor microenvironment has been shown to play a critical role in cancer progression and response to therapies. Endothelial cells (ECs) are a key component of the tumor microenvironment and promote cancer cell survival by secreting soluble factors that activate cancer-promoting signaling pathways. In this new perspective, researchers Omkar Desai and Rui Wang from Case Western Reserve University and University Hospitals Cleveland Medical Center discuss their studies and others that have identified HER3 as a key mediator of liver EC-induced chemoresistance and cancer cell growth in metastatic CRC and PDAC. “In complement to our studies, prior preclinical studies have shown that HER3-targeted therapies with antibodies and inhibitors have been effective in blocking tumor growth in several types of cancers [22, 23], specifically breast cancer [24], head and neck squamous cell carcinoma (HNSCC) [25], PDAC [25], and non-small cell lung cancer (NSCLC) [26]. However, translating the preclinical findings to clinical studies has shown limited impact on patient outcomes.” In this article, the researchers discuss that HER3-targeted therapies may be effective in treating patients with HER3-expressing CRC and PDAC, and highlight the importance of applying HER3 expression as a predictive biomarker for patient response to HER3-targeted therapies. They also discuss the challenges encountered in past clinical trials of HER3-targeted therapies, including the role of NRG1 gene fusions, alternative HER3 activation mechanisms, and adaptive resistance mechanisms. Finally, the team concludes by suggesting the future directions of HER3-targeted therapies, including novel approaches to overcome chemoresistance and promote cancer cell death. “In summary, we discovered that the surrounding liver EC microenvironment plays a key role in activating HER3 and promoting cell survival in mCRC and mPDAC, and potentially other types of cancer that metastasize to the liver.” DOI - https://doi.org/10.18632/oncotarget.28421 Correspondence to - Rui Wang - rxw517@case.edu Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28421 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - HER3, colorectal, pancreatic cancer, metastasis, microenvironment About Oncotarget Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957
CME credits: 0.25 Valid until: 28-02-2024 Claim your CME credit at https://reachmd.com/programs/cme/personalizing-the-treatment-of-recurrentmetastatic-hnscc-a-multifactorial-path/14953/ KEYNOTE-048 has opened new vistas to managing patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). Nonetheless, uncertainties remain in matching the correct patient with the correct strategy. Join Drs. Barbara Burtness and Nabil Saba as they parse the key trials and offer insight into building treatment algorithms designed to optimize outcomes for your patients with R/M HNSCC.=
A new research paper was published in Oncotarget's Volume 14 on February 2, 2023, entitled, “Everolimus downregulates STAT3/HIF-1α/VEGF pathway to inhibit angiogenesis and lymphangiogenesis in TP53 mutant head and neck squamous cell carcinoma (HNSCC).” TP53 mutant head and neck squamous cell carcinoma (HNSCC) patients exhibit poor clinical outcomes with 50–60% recurrence rates in advanced stage patients. In a recent phase II clinical trial, adjuvant therapy with everolimus (mTOR inhibitor) significantly increased 2-year progression-free survival in p53 mutated patients. TP53-driven mTOR activation in solid malignancies causes upregulation of HIF-1α and its target, downstream effector VEGF, by activating STAT3 cell signaling pathway. In this recent study, researchers Md Maksudul Alam, Janmaris Marin Fermin, Mark Knackstedt, Mackenzie J. Noonan, Taylor Powell, Landon Goodreau, Emily K. Daniel, Xiaohua Rong, Tara Moore-Medlin, Alok R. Khandelwal, and Cherie-Ann O. Nathan from LSU-Health Sciences Center investigated the effects of everolimus on the STAT3/HIF-1α/VEGF pathway in TP53 mutant cell lines and xenograft models. “The role of mTOR inhibitors (mTORi) as potent growth inhibitory and antiangiogenic/anti-lymphangiogenic agents in HNSCC is well established [18]. Moreover, mTORi significantly suppressed baseline invasiveness of endothelial and HNSCC tumor cells [19]. However, the underlying molecular mechanisms for mutant p53 protein-mediated activation of the mTOR pathway which drive the oncologic processes in HNSCC are yet to be elucidated.” Treatment with everolimus significantly inhibited cell growth in vitro and effectively reduced the growth of TP53 mutant xenografts in a minimal residual disease (MRD) model in nude mice. Everolimus treatment was associated with significant downregulation of STAT3/HIF-1α/VEGF pathway in both models. Further, treatment with everolimus was associated with attenuation in tumor angiogenesis and lymphangiogenesis as indicated by decreased microvessel density of vascular and lymphatic vessels in HN31 and FaDu xenografts. Everolimus downregulated the STAT3/HIF-1α/VEGF pathway to inhibit growth and in vitro tube formation of HMEC-1 (endothelial) and HMEC-1A (lymphatic endothelial) cell lines. “Our studies demonstrated that everolimus inhibits the growth of TP53 mutant tumors by inhibiting angiogenesis and lymphangiogenesis through the downregulation of STAT3/HIF-1α/VEGF signaling.” DOI: https://doi.org/10.18632/oncotarget.28355 Correspondence to: Cherie-Ann O. Nathan - cherieann.nathan@lsuhs.edu Keywords: TP53 mutant, HNSCC, angiogenesis, everolimus, mTOR About Oncotarget Oncotarget is a primarily oncology-focused, peer-reviewed, open access journal. Papers are published continuously within yearly volumes in their final and complete form, and then quickly released to Pubmed. On September 15, 2022, Oncotarget was accepted again for indexing by MEDLINE. Oncotarget is now indexed by Medline/PubMed and PMC/PubMed. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/OncotargetYouTube LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957
Head and neck squamous cell carcinoma (HNSCC) is the most prevalent form of head and neck cancer and is typically... The post Immunotherapy Updates in Head & Neck Cancer appeared first on VJOncology.
Head and neck squamous cell carcinoma (HNSCC) is the most prevalent form of head and neck cancer and is typically... The post Immunotherapy Updates in Head & Neck Cancer appeared first on VJOncology.
A new research paper was published in Oncotarget's Volume 13 on October 20, 2022, entitled, “Nectin-4 is widely expressed in head and neck squamous cell carcinoma.” Nectin-4 has been successfully established as a target molecule in locally advanced and metastatic bladder cancer. An antibody-drug conjugate (enfortumab-vedotin) directed against nectin-4 has shown marked tumor remission rates in this tumor type, which is known for high expression rates of nectin-4. As head and neck cancer and urothelial carcinomas share morphological and molecular similarities, researchers Christine Sanders, Jan-Frederic Lau, Dimo Dietrich, Sebastian Strieth, Peter Brossart, and Glen Kristiansen from University Medical Center Bonn and University Hospital Bonn aimed to evaluate Nectin-4 expression in head and neck squamous cell carcinoma (HNSCC). A previously described and clinically characterized cohort of HNSCC (n = 159) was analyzed by immunohistochemistry for Nectin-4 expression. The expression data was correlated to clinico-pathological parameters including patient outcome. Nectin-4 was found in 86.2% of HNSCC, with medium/high expression seen in 32.7% of cases. Non smokers and p16 positive HNSCC showed a higher expression of Nectin-4 (p < 0.005). There was no correlation of Nectin-4 with grading or tumor stage. Nectin-4 positive tumors showed significantly better survival (log rank p = 0.006). “Similar to urothelial carcinoma, Nectin-4 is found in the majority of HNSCC, which clearly warrants further studies to clarify if HNSCC also respond to targeted therapy with enfortumab-vedotin. Moreover, expression of Nectin-4 is associated with HPV infection and may serve as a prognostic marker in HNSCC.” DOI: https://doi.org/10.18632/oncotarget.28299 Correspondence to: Glen Kristiansen - Email: glen.kristiansen@ukbonn.de Video - https://www.youtube.com/watch?v=tDY21YpFsKc Keywords: Nectin-4, enfortumab-vedotin, HNSCC, p16 About Oncotarget: Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media: Twitter – https://twitter.com/Oncotarget Facebook – https://www.facebook.com/Oncotarget YouTube – www.youtube.com/c/OncotargetYouTube Instagram – https://www.instagram.com/oncotargetjrnl/ LinkedIn – https://www.linkedin.com/company/oncotarget/ Pinterest – https://www.pinterest.com/oncotarget/ LabTube – https://www.labtube.tv/channel/MTY5OA SoundCloud – https://soundcloud.com/oncotarget For media inquiries, please contact: media@impactjournals.com Oncotarget Journal Office 6666 East Quaker Str., Suite 1A Orchard Park, NY 14127 Phone: 1-800-922-0957 (option 2)
Listen to a blog summary of a trending research paper published in Volume 13, entitled, “NF-κB over-activation portends improved outcomes in HPV-associated head and neck cancer.” ______________________________ Over the last 10 years in the United States, the human papillomavirus (HPV) has caused more head and neck squamous cell carcinomas (HNSCC) than uterine cervical cancers. Primarily caused either by exposure to HPV or to ethanol or tobacco, HNSCC is a disease that impairs fundamental tissues involved in respiration, speech and digestion. HPV-positive and -negative HNSCC have contrasting clinical, epidemiological and histological features. “A major discovery in the recent past is that HPV associated HNSCC have improved survival compared to tobacco associated tumors.” Therefore, treating HNSCC in accordance with HPV status is crucial for avoiding unnecessarily harsh therapeutic side effects in HPV+ HNSCC patients. However, while oncologic outcomes among patients with HPV+ HNSCC are generally favorable, approximately 30% experience a more aggressive disease course and recurrence. Coupled with increasing incidence worldwide, this highlights a growing need for the development of effective clinical stratification tools to accurately identify HPV+ HNSCC patients who have a good or poor prognosis. In a new study, researchers—from Columbia University, University of Illinois Cancer Center, University of North Carolina at Chapel Hill, and Yale School of Medicine—developed a new tool aimed at better classifying HPV+ HNSCC patients with good or poor prognosis in an effort to personalize treatment and improve patient outcomes. Their trending research paper was published in Oncotarget on May 24, 2022, and entitled, “NF-κB over-activation portends improved outcomes in HPV-associated head and neck cancer.” “To improve on genomic classification, we designed this study to provide a foundation for development of NF-κB related, RNA based classification strategies to better identify HPV+ HNSCC patients with good or poor prognosis that could potentially aid in future efforts towards treatment personalization.” Full blog - https://www.oncotarget.org/2022/05/26/new-tool-uses-nf-%ce%bab-activity-to-classify-hpv-head-and-neck-cancer/ DOI - https://doi.org/10.18632/oncotarget.28232 Correspondence to - Wendell G. Yarbrough - dell@med.unc.edu, and Natalia Issaeva - natalia.isaeva@med.unc.edu Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28232 Press release - https://www.oncotarget.com/news/pr/oncotarget-nf-b-over-activation-portends-improved-outcomes-in-hpv-associated-head-and-neck-cancer/ Keywords - HPV, head and neck cancer, CYLD, TRAF3, NF-κB About Oncotarget Oncotarget is a peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/OncotargetYouTube LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Oncotarget is published by Impact Journals, LLC: https://www.ImpactJournals.com Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957
BUFFALO, NY- May 25, 2022 – A new research paper was published in Oncotarget, entitled, “NF-κB over-activation portends improved outcomes in HPV-associated head and neck cancer.” Head and neck squamous cell carcinoma (HNSCC) is a devastating disease that impairs fundamental tissues involved in respiration, phonation and digestion. HNSCC is primarily caused by exposure to either ethanol and tobacco or the human papillomavirus (HPV). Among patients with HPV+ HNSCC, there is a growing clinical demand to develop robust stratification tools to accurately identify patients with good or poor prognosis. “While oncologic outcomes for HPV+ HNSCC are generally favorable, treatment paradigms developed for HPV-negative disease burden many survivors of HPV+ HNSCC with lifelong debilitating treatment-associated side effects [10]. On the other hand, ~30% of HPV+ HNSCC patients exhibit a more aggressive disease course and suffer recurrence [11, 12].” Somatic mutations or deletions in TRAF3 or CYLD identified a subset of HPV+ HNSCC associated with improved outcome. A cross talk between canonical and non-canonical NF-κB signaling suggests that TRAF3 and CYLD affect both NF-κB pathways. “Herein, we demonstrate that an RNA-based classifier trained on tumors harboring these mutations may improve prognostic classification (Figure 3A, 3B, Figure 4B and Supplementary Figure 1).” To improve on genomic classification, researchers designed the current study to provide a foundation for development of NF-κB related, RNA based classification strategies to better identify HPV+ HNSCC patients with good or poor prognosis that could potentially aid in future efforts towards treatment personalization. “This report validates and expands on our findings that significant expression changes related to NF-κB activity occur in the subset of HPV+ HNSCC tumors marked by TRAF3 or CYLD mutations. We are planning future studies investigating the importance of ‘long-tail' mutations in the NF-κB pathway which might further illuminate the origins of NF-κB dysregulation in HPV+ HNSCC.” “Given that methods to identify patients for deintensified therapy are imperfect, our improved classifiers may serve as prognostic biomarker to help clinicians with therapeutic decisions.” DOI: https://doi.org/10.18632/oncotarget.28232 Correspondence to: Wendell G. Yarbrough and Natalia Issaeva Email: dell@med.unc.edu and natalia.isaeva@med.unc.edu Keywords: HPV, head and neck cancer, CYLD, TRAF3, NF-κB About Oncotarget: Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science. To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media: Twitter – https://twitter.com/Oncotarget Facebook – https://www.facebook.com/Oncotarget YouTube – www.youtube.com/c/OncotargetYouTube Instagram – https://www.instagram.com/oncotargetjrnl/ LinkedIn – https://www.linkedin.com/company/oncotarget/ Pinterest – https://www.pinterest.com/oncotarget/ LabTube – https://www.labtube.tv/channel/MTY5OA SoundCloud – https://soundcloud.com/oncotarget For media inquiries, please contact: media@impactjournals.com.
In this episode of IMPACT Medicom's podcast series on immunotherapies in Head and Neck Squamous Cell Carcinoma, we discuss the medical oncologist's role in managing patients with HNSCC, and how immunotherapies fit in to their practice.Our Guest:Dr. Martin Smoragiewicz is a Medical Oncologist at the Odette Cancer Centre, part of Sunnybrook Health Sciences Centre in Toronto, Ontario. His clinical expertise is in Genitourinary and Head & Neck cancers and his research focuses on improving therapeutics, with a special interest in immunotherapy. Dr. Smoragiewicz is the principal investigator on numerous clinical trials, and the lead for Head & Neck clinical trials at the Odette Cancer Centre.This podcast episode was sponsored by Merck Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
Welcome to the second episode of IMPACT Medicom's podcast series on Immunotherapy in Head and Neck Squamous Cell Carcinomas (HNSCC). This episode includes a discussion of:The role of the surgical oncologist in managing patients with HNSCCHow immunotherapy fits into to the surgical oncologist's practice Our Guest:Our guest is Dr. Antoine Eskander, a head and neck surgical oncologist at Sunnybrook Health Sciences Centre and Assistant professor in the department of otolaryngology at the University of Toronto. He is also an adjunct scientist at the Institute for Clinical Evaluative Sciences. This podcast episode was sponsored by Merck Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
Welcome to the first episode of IMPACT Medicom's podcast series on Immunotherapy in Head and Neck Squamous Cell Carcinomas. This episode includes a discussion of:The role of the pathologist in the management of head and neck cancers PD-L1 testing as a predictive biomarker for immunotherapy in HNSCCImproving the testing process for PD-L1 Our Guest:Our guest is Dr. Matthew Cecchini, Pathologist in the Department of Pathology and Laboratory Medicine at London Health Sciences Centre and Assistant Professor at Western University in London Ontario Canada. Dr. Cecchini specializes in pulmonary, head and neck, and molecular pathology. His research interests include the application of digital and machine learning tools in pathology. This podcast episode was sponsored by Merck Canada.If you enjoy our podcast, please review and subscribe. For more podcasts and other medical education content, visit our website at: https://www.impactmedicom.com
Head and neck cancer is a group of various tumors located in the oral cavity, oropharynx, larynx, and hypopharynx. Head and neck cell squamous-cell carcinomas (HNSCC) often result from tobacco use or human papillomavirus (HPV+) infection. In locally advanced HNSCC, the current therapies used are combined surgery, radiotherapy and chemotherapy. Despite the use of traditional treatments, up to 50% of patients relapse due to the increase in mutational burden as HNSCC advances. Few studies have investigated the therapeutic potential of neoantigens in HNSCC tumors. “Prior work has characterized changes in the mutation burden between primary and recurrent tumors; however, little work has characterized the changes in neoantigen evolution.” Neoantigens are new proteins/antigens that form on cancer cells after mutations occur in the tumor DNA. Certain neoantigens can promote anti-tumor immune responses and are potentially capable of controlling tumor progression. In an effort to characterize genomic and neoantigen changes in patients with HNSCC, researchers—from Washington University in St. Louis, Columbia University, St. Louis Children's Hospital, and Siteman Cancer Center—investigated 23 paired primary and recurrent HNSCC tumors. Their paper, entitled, “Genomic and neoantigen evolution from primary tumor to first metastases in head and neck squamous cell carcinoma,” was chosen as the cover paper for Oncotarget's Volume 12, Issue #6. Full blog -https://www.oncotarget.org/2022/01/13/primary-versus-metastatic-head-and-neck-tumors/ Press release - https://www.oncotarget.com/news/pr/genomic-and-neoantigen-evolution-in-head-and-neck-squamous-cell-carcinoma/ Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.27907 DOI - https://doi.org/10.18632/oncotarget.27907 Full text - https://www.oncotarget.com/article/27907/text/ Correspondence to - Brian A. Van Tine - bvantine@wustl.edu Keywords - head and neck squamous cell carcinoma, neoantigens, mutational evolution, tumor relapse, immune cell infiltration About Oncotarget: Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit www.oncotarget.com or follow us: SoundCloud - @oncotarget Facebook - www.facebook.com/Oncotarget/ Twitter - twitter.com/oncotarget LinkedIn - www.linkedin.com/company/oncotarget Instagram - www.instagram.com/oncotargetjrnl/ YouTube - www.youtube.com/OncotargetYouTube Pinterest - www.pinterest.com/oncotarget/ Reddit - www.reddit.com/user/Oncotarget/ Oncotarget is published by Impact Journals, LLC please visit www.ImpactJournals.com or connect with @ImpactJrnls Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957x105
Oncotarget published "Genomic and neoantigen evolution from primary tumor to first metastases in head and neck squamous cell carcinoma" which reported that prior work has characterized changes in the mutation burden between primary and recurrent tumors; however, little work has characterized the changes in neoantigen evolution. These authors characterized genomic and neoantigen changes between 23 paired primary and recurrent head and neck squamous cell carcinoma (HNSCC) tumors. Within these tumors, they identified 6 genes which have predicted neoantigens in 4 or more patients. Within HNSCC tumors examined in this Oncotarget research paper, there are neoantigens in shared genes by a subset of patients. The presence of neoantigens in these shared genes may promote an anti-tumor immune response which controls tumor progression. Dr. Brian A. Van Tine from The Washington University in St. Louis, The St. Louis Children's Hospital as well as The Siteman Cancer Center said, "Head and neck cancer are a group of heterogeneous tumors with an estimated 644,000 new cases per year worldwide." The infiltration of immune cells, including T cells, into tumors is associated with improved outcomes and longer survival in HNSCC. The infiltrating T cells release granules containing perforin and granzyme A and B which directly kill tumor cells or release other cytokines and chemokines that promote the anti-tumor immune response and alter the tumor microenvironment. For example, infiltrating T cells release interferon gamma which increases expression of PD-L1 and CTLA-4, which may increase the efficacy of immune checkpoint therapy. Multiple studies have characterized changes in mutation burden in HNSCC, when comparing primary and metastatic tumors, no studies have characterized the shifting neoantigen burden between primary and metastatic tumors within HNSCC. In this Oncotarget study, the authors characterized the mutational and neoantigen burden between primary and first recurrence tumors in 23 patients with HNSCC. The Van Tine Research Team concluded in their Oncotarget Research Output that there is a shifting neoantigen burden as there are unique neoantigens in primary tumors and different unique neoantigens in the recurrent/metastatic tumors. The patients which have these neoantigens in shared genes are patients which have higher total numbers of neoantigens. What is clear is that patients with neoantigens in these shared genes also tend to have increased duration of survival with disease. The increase in neoantigens and duration of survival with disease tends to be associated with increased CD3 CD8 density in the tumor and CD8A expression. This suggests that patients with these shared neoantigens are associated with increased CD8 T cell infiltration and increased cytotoxic activity, which extends the patient's life. DOI - https://doi.org/10.18632/oncotarget.27907 Full text - https://www.oncotarget.com/article/27907/text/ Correspondence to - Brian A. Van Tine - bvantine@wustl.edu Keywords - head and neck squamous cell carcinoma, neoantigens, mutational evolution, tumor relapse, immune cell infiltration About Oncotarget Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnls Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957x105
This podcast highlights original research published in the October 2021 issue of Otolaryngology–Head and Neck Surgery, the official journal of the American Academy of Otolaryngology—Head and Neck Surgery (AAO-HNS) Foundation. Pathologic extranodal extension (ENE) is an important adverse feature for human papillomavirus (HPV)–negative head and neck squamous cell carcinoma (HNSCC), but the prognostic significance of microscopic ENE (ENEmi) and role of adjuvant concurrent chemoradiation (CRT) for ENEmi remain unclear. This study evaluates (1) the prognostic significance of ENEmi in HPV-negative HNSCC and (2) whether adjuvant CRT is associated with improved overall survival (OS) for these patients. In conclusion, for patients with HPV-negative HNSCC, pN+ with ENEmi is associated with worse OS than pN+ without ENE. However, for patients with ENEmi, concurrent CRT is not associated with improved OS relative to RT. The optimal adjuvant paradigm for ENEmi requires additional investigation. Click here to read the full article.
CME credits: 0.25 Valid until: 30-07-2022 Claim your CME credit at https://reachmd.com/programs/cme/updates-head-and-neck-cancer-treatment-integrating-checkpoint-inhibitor-therapy-improve-outcomes/12701/ Head and neck squamous cell carcinomas (HNSCC) represent a significant healthcare burden due to associated morbidity and mortality. Most patients survive less than a year after diagnosis and report a poor quality of life. Tune in to this chapterized content as two leading experts, Drs. Ezra Cohen and Barbara Burtness, discuss recent clinical trial data and strategies to improve sequencing and treatment selection. Find out how checkpoint inhibitors are shifting the treatment landscape of HNSCC and what this means for your patients.
CME credits: 0.25 Valid until: 30-07-2022 Claim your CME credit at https://reachmd.com/programs/cme/updates-head-and-neck-cancer-treatment-integrating-checkpoint-inhibitor-therapy-improve-outcomes/12701/ Head and neck squamous cell carcinomas (HNSCC) represent a significant healthcare burden due to associated morbidity and mortality. Most patients survive less than a year after diagnosis and report a poor quality of life. Tune in to this chapterized content as two leading experts, Drs. Ezra Cohen and Barbara Burtness, discuss recent clinical trial data and strategies to improve sequencing and treatment selection. Find out how checkpoint inhibitors are shifting the treatment landscape of HNSCC and what this means for your patients.
Host: Ezra Cohen, MD Guest: Barbara Burtness, MD Head and neck squamous cell carcinomas (HNSCC) represent a significant healthcare burden due to associated morbidity and mortality. Most patients survive less than a year after diagnosis and report a poor quality of life. Tune in to this chapterized content as two leading experts, Drs. Ezra Cohen and Barbara Burtness, discuss recent clinical trial data and strategies to improve sequencing and treatment selection. Find out how checkpoint inhibitors are shifting the treatment landscape of HNSCC and what this means for your patients.
This week's cover paper of Oncotarget (Volume 12, Issue 14) is entitled, "Esomeprazole enhances the effect of ionizing radiation to improve tumor control," by researchers from Baylor College of Medicine, University of Texas MD Anderson Cancer Center, and Texas Children's Hospital. Abstract: The resistance of cancer cells to radiation-based treatment is a major clinical challenge confounding standard of care in cancer. This problem is particularly notable in many solid tumors where cancer cells are only partially responsive to radiation therapy. Combination of radiation with radiosensitizers is able to enhance tumor cell killing. However, currently available radiosensitizers are associated with significant normal tissue toxicity. Accordingly, there is an unmet need to develop safer and more effective radiosensitizers to improve tumor control. Here, we evaluated the radiosensitizing effect of the FDA-approved drug esomeprazole in normal and radioresistant human head and neck squamous cell carcinoma (HNSCC) cells in vitro, and in a mouse model of HNSCC. For the in vitro studies, we used cancer cell colony formation (clonogenicity) assay to compare cancer cell growth in the absence or presence of esomeprazole. To determine mechanism(s) of action, we assessed cell proliferation and profiled cell cycle regulatory proteins. In addition, we performed reverse phase protein array (RPPA) study to understand the global effect of esomeprazole on over 200 cancer-related proteins. For the in vivo study, we engrafted HNSCC in a mouse model and compared tumor growth in animals treated with radiation, esomeprazole, and combination of radiation with esomeprazole. We found that esomeprazole inhibits tumor growth and dose-dependently enhances the cell killing effect of ionizing radiation in wildtype and p53-mutant radioresistant cancer cells. Mechanistic studies demonstrate that esomeprazole arrests cancer cells in the G1 phase of the cell cycle through upregulation of p21 protein and inhibition of cyclin-dependent kinases (Cdks) type 1 (Cdk1) and type 2 (Cdk2). In vivo data showed greater tumor control in animals treated with combination of radiation and esomeprazole compared to either treatment alone, and that this was associated with inhibition of cell proliferation in vivo. In addition, combination of esomeprazole with radiation significantly impaired repair following radiation-induced DNA damage. Our studies indicate that esomeprazole sensitizes cancer cells to ionizing radiation, and is associated with upregulation of p21 to arrest cells in the G1 phase of the cell cycle. Our findings have significant therapeutic implications for the repurposing of esomeprazole as a radiosensitizer in HNSCC and other solid tumors. Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28008 DOI - https://doi.org/10.18632/oncotarget.28008 Full text - https://www.oncotarget.com/article/28008/text/ Correspondence to - Yohannes T. Ghebre - yohannes.ghebre@bcm.edu Keywords - esomeprazole, proton pump inhibitors, ionizing radiation, radiosensitization, tumor control About Oncotarget Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget YouTube - https://www.youtube.com/c/OncotargetYouTube/ LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Oncotarget is published by Impact Journals, LLC please visit https://www.ImpactJournals.com or connect with @ImpactJrnls Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957
Listen to short summaries of the latest oncology-focused research published in this week's issue of Oncotarget, Volume 12, Issue 13. https://www.oncotarget.com/archive/v12/i13/ Cover Paper “Oncogenic transformation of NIH/3T3 cells by the overexpression of L-type amino acid transporter 1, a promising anti-cancer target” https://doi.org/10.18632/oncotarget.27981 News “A new class of radiosensitizers for glioblastoma” https://doi.org/10.18632/oncotarget.27970 (PDF Download) Research Paper “A platform for locoregional T-cell immunotherapy to control HNSCC recurrence following tumor resection” https://doi.org/10.18632/oncotarget.27982 Research Paper “Human papilloma virus circulating tumor DNA assay predicts treatment response in recurrent/metastatic head and neck squamous cell carcinoma” https://doi.org/10.18632/oncotarget.27992 Research Paper “Association of high-sensitivity C-reactive protein and odds of breast cancer by molecular subtype: analysis of the MEND study” https://doi.org/10.18632/oncotarget.27991 Research Paper “Glucocorticoid receptor antagonism promotes apoptosis in solid tumor cells” https://doi.org/10.18632/oncotarget.27989 Research Paper “TERT and its binding protein: overexpression of GABPA/B in high grade gliomas” https://doi.org/10.18632/oncotarget.27985 Review “Cross-talks in colon cancer between RAGE/AGEs axis and in-flammation/immunotherapy” https://doi.org/10.18632/oncotarget.27990 Review “Cancer-epigenetic function of the histone methyltransferase KMT2D and therapeutic opportunities for the treatment of KMT2D-deficient tumors” https://doi.org/10.18632/oncotarget.27988 Research Perspective “Targeting super-enhancers reprograms glioblastoma central carbon metabolism” https://doi.org/10.18632/oncotarget.27938 Editorial Perspective “Polo-like kinase inhibition as a therapeutic target in acute myeloid leukemia” https://doi.org/10.18632/oncotarget.27919 (PDF Download) Editorial “The formation of pre-effectors in the steady state opens a new perspective for cancer immunosurveillance” https://doi.org/10.18632/oncotarget.27967 (PDF Download) Editorial “Mechanisms of gefitinib-induced interstitial pneumonitis: why and how the TKI perturbs innate immune systems?” https://doi.org/10.18632/oncotarget.27958 (PDF Download) Keywords - oncogenicity, glioblastoma, head and neck cancer, immunotherapy, tumors, glioma, colon cancer, epigenetics, cancer immunosurveillance, gefitinib, AML, breast cancer, cancer, science, research, oncology About Oncotarget Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit https://www.oncotarget.com/ or connect with: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget LinkedIn - https://www.linkedin.com/company/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/oncotargetyoutube Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget Oncotarget is published by Impact Journals, LLC. Please visit https://www.impactjournals.com/ or connect with @ImpactJrnls Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957
In the cover paper of this week's issue of Oncotarget, titled: "Genomic and neoantigen evolution from primary tumor to first metastases in head and neck squamous cell carcinoma," the aim of the researchers in this exploratory study was to characterize the genomic and neoantigen changes in 23 paired primary and recurrent HNSCC tumors. Of the 23 patients in this study, 17 were male and 14 were tobacco smokers. The distribution of primary tumor location was nine in the oral cavity, seven in the oropharynx, six in the larynx, and one in the hypopharynx. The researchers note that all seven patients with an oropharyngeal primary tumor were HPV+. All 23 patients received some combination of traditional treatment. “To understand the recurrent mutation effect between primary and recurrent/metastatic tumors, we extract recurrently mutated genes (>1 sample mutated gene) from primary and recurrent/metastatic samples, separately.” Read the full study here: https://doi.org/10.18632/oncotarget.27907 Oncotarget Volume 12, Issue 6: https://www.oncotarget.com/archive/v12/i6/ About Oncotarget: Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit www.oncotarget.com or follow us: SoundCloud - @oncotarget Facebook - www.facebook.com/Oncotarget/ Twitter - twitter.com/oncotarget LinkedIn - www.linkedin.com/company/oncotarget Instagram - www.instagram.com/oncotargetjrnl/ YouTube - www.youtube.com/OncotargetYouTube Pinterest - www.pinterest.com/oncotarget/ Reddit - www.reddit.com/user/Oncotarget/ Oncotarget is published by Impact Journals, LLC please visit www.ImpactJournals.com or connect with @ImpactJrnls Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957x105
Listen to short summaries of the latest oncology-focused research literature published in this week's issue of Oncotarget. https://www.oncotarget.com/archive/v12/i6/ Oncotarget Volume 12, Issue 6 features: COVER PAPER: "Genomic and neoantigen evolution from primary tumor to first metastases in head and neck squamous cell carcinoma." Institutions: Washington University in St. Louis, Columbia University, St. Louis Children’s Hospital, Siteman Cancer Center Quote: “We characterized genomic and neoantigen changes between 23 paired primary and recurrent HNSCC tumors. Twenty-three biopsies from patients originally diagnosed with locally advanced disease were identified from the Washington University tumor bank.” doi.org/10.18632/oncotarget.27907 EDITORIAL: "Innovating and expanding weight loss strategies for breast cancer survivors." Institution: Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Quote: “Compared to those with ideal body weight, women who have excess weight experience inferior outcomes once diagnosed with breast cancer, despite standard local and adjuvant therapy [6].” https://doi.org/10.18632/oncotarget.27898 RESEARCH PERSPECTIVE: "Pancreatic cancer driver mutations are targetable through distant alternative RNA splicing dependencies." Institutions: The Johns Hopkins University School of Medicine, Dartmouth Geisel School of Medicine and Norris Cotton Cancer Center, Yale University, Stony Brook University Renaissance School of Medicine Quote: “Here, we review PDAC pathogenesis as it relates to fundamental ARS [Alternative RNA splicing] biology, with an extension to implications for PDAC patient clinical management.” doi.org/10.18632/oncotarget.27901 RESEARCH PAPER: "A high-content AlphaScreen™ identifies E6-specific small molecule inhibitors as potential therapeutics for HPV+ head and neck squamous cell carcinomas." Institutions: Loma Linda University, University of Kansas Quote: “Herein we describe our search for small molecule inhibitors that disrupt binding of E6 to caspase 8 using AlphaScreen technology™ (Perkin Elmer, Waltham, MA). This technology is a proximity-based platform for identifying hit compounds that perturb a specific interaction between two beaded proteins. Using this approach, we interrogated a library of over 5000 small molecules for compounds that antagonize E6 binding to caspase 8.” doi.org/10.18632/oncotarget.27908 RESEARCH PAPER: "Characterization of the inflammatory microenvironment and hepatic macrophage subsets in experimental hepatocellular carcinoma models." Institution: Ghent University Quote: “Here, we characterized the tumor microenvironment and the proportion and transcriptional profile of hepatic macrophages (Mφ) in two commonly used HCC mouse models.” doi.org/10.18632/oncotarget.27906 RESEARCH PAPER: "Molecular characterization of lung squamous cell carcinoma tumors reveals therapeutically relevant alterations." Institutions: Tata Memorial Centre, Homi Bhabha National Institute Quote: “We performed survival analyses of lung squamous cell carcinoma patients harboring therapeutically relevant alterations identified by whole exome sequencing and mass spectrometry-based validation across 430 lung squamous tumors.” doi.org/10.18632/oncotarget.27905 About Oncotarget: Oncotarget is a bi-weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit www.oncotarget.com or follow us: SoundCloud - @oncotarget Facebook - www.facebook.com/Oncotarget/ Twitter - twitter.com/oncotarget LinkedIn - www.linkedin.com/company/oncotarget Instagram - www.instagram.com/oncotargetjrnl/ YouTube - www.youtube.com/OncotargetYouTube Pinterest - www.pinterest.com/oncotarget/ Reddit - www.reddit.com/user/Oncotarget/ Oncotarget is published by Impact Journals, LLC please visit www.ImpactJournals.com or connect with @ImpactJrnls Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957x105
Immune checkpoint inhibitors are a relatively new treatment option for patients with metastatic, unresectable head and neck squamous cell carcinoma (HNSCC), and so they have not yet been incorporated into clinical practice guidelines. For this reason, we interview Professor Frederic Peyrade, Head of Clinical Research and Professor of Oncology, Antoine Lacassagne Cancer Centre, France, to get expert advice on incorporating immune checkpoint inhibitors into current treatment protocols. References - Grégoire V, et al. Ann Oncol. 2009; 20 Suppl 4: 121-2 - Dimitrios Colevas, et al. J Natl Compr Canc Netw. 2018 May; 16(5): 479-490 - Cohen, et al. J Immunother Cancer. 2019 Jul 15; 7(1): 184 Access more free education today! Visit the website, follow us on Twitter (@onckip) or connect on LinkedIn. This independent educational activity is supported by an educational grant from Merck, Sharpe & Dohme Corp. The educational content has been developed by Liberum IME in conjunction with an independent steering committee; MSD corp. has had no influence on the content of this education.
Volume 11, Issue 28 of Oncotarget features "Lipid and protein tumor markers for head and neck squamous cell carcinoma identified by imaging mass spectrometry" by Schmidt et, al. which reported that the authors used MALDI imaging mass spectrometry and immunohistochemistry to seek tumor-specific expression of proteins and lipids in HNSCC samples. DOI - https://doi.org/10.18632/oncotarget.27649 Full text - https://www.oncotarget.com/article/27649/text/ Correspondence to - Zsolt Balogi - zsolt.balogi@aok.pte.hu and László Márk - laszlo.mark@aok.pte.hu Keywords - Imaging mass spectrometry, tumor marker, lipid tumor marker, S100A8, S100A9 About Oncotarget Oncotarget is a weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit https://www.oncotarget.com or connect with: SoundCloud - https://soundcloud.com/oncotarget Facebook - https://www.facebook.com/Oncotarget/ Twitter - https://twitter.com/oncotarget LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Oncotarget is published by Impact Journals, LLC please visit http://www.ImpactJournals.com or connect with @ImpactJrnls Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957x105
Volume 11 Issue 25 of @Oncotarget reported that the authors aimed to characterize the bacteriome, mycobiome, and mycobiome-bacteriome interactions of oral wash in Head and neck squamous cell carcinoma, or HNSCC, patients and to determine if they are distinct from those of the oral wash of matched non-Head and neck squamous cell carcinoma patients. Oral wash samples were collected from 46 individuals with HNSCC and 46 controls for microbiome analyses. A number of organisms were identified as being differentially abundant between oral wash samples from patients with HNSCC and oral wash samples from those without HNSCC. Of note, strains of Candida albicans and Rothia mucilaginosa were differentially abundant and Schizophyllum commune was depleted in those with HNSCC compared to oral wash from those without HNSCC. Our results suggest that the oral cavity of HNSCC patients harbors unique differences in the mycobiome, bacteriome, and microbiome interactions when compared to those of control patients. Dr. Charis Eng from The Cleveland Clinic as well as The Case Western Reserve University School of Medicine said, "Head and neck squamous cell carcinoma (HNSCC) refers to cancer arising from the squamous epithelium of the oral cavity, pharynx, nasopharynx, and larynx." Not all patients with these risk factors develop HNSCC, and some patients with HSNCC lack these risk factors. There is, therefore, a need to identify additional risk factors to better predict which patients, particularly among those at high risk, will develop HNSCC. The oral microbiome contains not only bacterial communities but also fungal communities comprising the oral mycobiome. Fungal communities have the potential not only to independently influence the environment of the oral cavity but also to interact with oral bacterial communities. Therefore, the authors sought to identify and characterize differences in the bacteriome and mycobiome profiles of patients with HNSCC versus healthy cancer-free patients, using oral wash as template biospecimen. The Eng Research Team concluded in their Oncotarget Research Paper that they found inter and intra-kingdom correlations within the oral wash. Although the composition of the clusters within networks appeared largely similar between case and control oral wash, there were some interactions that differed. A positive relationship between two organisms could suggest that they occupy similar niches or even that they share a symbiotic relationship. A negative relationship, by contrast, could point to two organisms that either compete against each other through varying means. They went on to note multiple interactions that were opposing when considering case oral wash versus control oral wash suggests not only changes in the composition of the microbiome but also in how members of the microbiome interact with each other in HNSCC patients. The relationship between Alloscardovia and Candida, for example, was negative, in case oral wash but positive in control oral wash. Such shifts could signal the presence of HNSCC in an oral wash based screening tool for Head and neck squamous cell carcinoma. DOI - https://doi.org/10.18632/oncotarget.27629 Full text - https://www.oncotarget.com/article/27629/text/ Correspondence to - Charis Eng - engc@ccf.org Keywords - microbiome, bacteriome, mycobiome, head and neck squamous cell carcinoma, cancer About Oncotarget Oncotarget is a weekly, peer-reviewed, open access biomedical journal covering research on all aspects of oncology. To learn more about Oncotarget, please visit https://www.oncotarget.com Oncotarget is published by Impact Journals, LLC please visit http://www.ImpactJournals.com or connect with @ImpactJrnls Media Contact MEDIA@IMPACTJOURNALS.COM 18009220957x105
The third EP from The 1975 - Music For Cars. Featuring Anobrain, HNSCC, Head.Cars.Bending and Me... Chocolate coming soon.
Dan Passeri, CEO, Cue Biopharma discusses their proprietary Immuno-STAT(TM) platform. Cue Biopharma is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells within the body to transform the treatment of cancer and autoimmune diseases. The platform is designed to harness the body's intrinsic immune system response without the need for ex vivo manipulation. Cue is currently conducting a Phase 1 study in HPV16-driven head and neck cancer and partnering with Merck to develop treatments for autoimmune diseases. #immunooncology #HNSCC. #TCells @CueBiopharma CueBiopharma.com Listen to the podcast here. Download the entire transcript from this episode page TRANSCRIPT Page 1: Karen Jagoda: Welcome to the empoweredpatientpodcast.com show. I'm Karen Jagoda, and my guest today is Dan Passeri. He's the CEO of Cue Biopharma. That's cuebiopharma.com. And I recently talked with Anish Suri, who is the Chief Scientific Officer at Cue, and I thought it was such an interesting story that I thought it was also a good idea to get the CEO of the company on the show to give us a little bit of an update and perhaps a little bit more in the way of details. So welcome to the show today, Dan. Dan Passeri: Thanks, Karen. Appreciate it. Karen Jagoda: So let's just talk a little bit about where Cue fits into the landscape of immuno-oncology companies. Dan Passeri: Sure. Immuno-oncology is obviously a very broad, encompassing category, and what it really covers is any approach that is meant to stimulate the immune system in some manner, that is meant to have clinical activity against cancer. And there's a myriad of approaches, but ultimately, no matter what approach is being taken, the objective is to stimulate the effective components of the immune system that can identify and attack cancer. Dan Passeri: What we do is actually quite distinctive in that the majority of approaches have tried to stimulate T-cells in various ways by taking them out of the body, for instance. And we've all heard of all these various cell therapy approaches, CAR T being the best publicized and characterized. And that's where you're taking T-cells out of the patient, you're genetically altering them to have a particular receptor that recognizes cancer, and infusing them back in. Dan Passeri: There are also cell therapy approaches where they take the cells out and use particular proteins that are represented on cancer, and then those T-cells will recognize that protein, and they use something called IL-2, Interleukin-2. It's an approved drug called proleukin, and they'll stimulate the T-cells, and then they infuse them back into the body. Dan Passeri: What we're doing is quite a different approach, and we believe it's a transformative approach in that we are using a biologic engineering category to stimulate T-cells directly in the patient's body. So it basically removes the need for having to extract T-cells out of the patient and the cumbersome manipulations, and we believe what we'll have is a potential breakthrough in the space where we can use our biologic to engage the desired T-cells. Now, that is only those T-cells that will recognize the protein on the cancer, activate those T-cells, and make many copies of them so that they then will identify the tumor cells, attack them, and destroy them. So that's the broad overview of what we're doing. Karen Jagoda: So when I heard you describe what you're up to, it sounded like there were lots of advantages. One, a time factor. You don't have to take the cells out and put them back in the body after a certain period of time. But also it sounds like you might be able to reduce the unintended consequences or the side effects. Can you say a little bit about what goes on when you approach the cancer in this way? Download the entire transcript. Sponsored by
© 2020-2025 Ivy Podcast Discovery LLC
